A 63-year-old man with COPD (FEV1 45% predicted, two hospitalised exacerbations in the last year) is on long-acting muscarinic antagonist (LAMA) monot...

Question

A 63-year-old man with COPD (FEV1 45% predicted, two hospitalised exacerbations in the last year) is on long-acting muscarinic antagonist (LAMA) monotherapy. He continues to have dyspnoea and exacerbations. According to the 2023 Canadian Thoracic Society pharmacotherapy guideline, what is the MOST appropriate next step?

Accepted Answer

Escalate to dual long-acting bronchodilator therapy (LAMA/LABA)

Answer

Continue LAMA monotherapy

Answer

Switch to short-acting beta agonist (SABA) monotherapy

Answer

Add inhaled corticosteroid (ICS) monotherapy

Answer

Start chronic oral prednisone 5 mg daily

ca-mccqe1 MCQ (SBA): Chronic obstructive pulmonary disease - stepwise pharmacotherapy